Thermo Fisher Scientific (TMO) stock price, revenue, and financials

Thermo Fisher Scientific market cap is $214.7 b, and annual revenue was $39.21 b in FY 2021

View Company

+3.46(+0.64%)

$214.7 B

TMO Mkt cap, 24-Jun-2022

$11.8 B

Thermo Fisher Scientific Revenue Q1, 2022

Thermo Fisher Scientific Gross profit (Q1, 2022)5.5 B

Thermo Fisher Scientific Gross profit margin (Q1, 2022), %46.2%

Thermo Fisher Scientific Net income (Q1, 2022)2.2 B

Thermo Fisher Scientific EBIT (Q1, 2022)2.8 B

Thermo Fisher Scientific Cash, 02-Apr-20222.8 B

Thermo Fisher Scientific EV245.2 B

Thermo Fisher Scientific Revenue

Thermo Fisher Scientific revenue was $39.21 b in FY, 2021 which is a 21.7% year over year increase from the previous period.

Embed Graph

Thermo Fisher Scientific Revenue Breakdown

Embed Graph

Thermo Fisher Scientific revenue breakdown by business segment: 37.0% from Life Sciences Solutions, 14.4% from Analytical Instruments, 13.4% from Specialty Diagnostics and 35.2% from Laboratory Products and Services

Thermo Fisher Scientific revenue breakdown by geographic segment: 8.8% from China, 48.2% from United States and 43.0% from Other

Annual

USD	FY, 2019	FY, 2020	FY, 2021
Revenue	25.5b	32.2b	39.2b
Revenue growth, %	5%	26%	22%
Cost of goods sold	14.2b	16.2b	19.6b
Gross profit	11.3b	16.0b	19.6b
Gross profit Margin, %	44%	51%	50%
R&D expense	1.0b	1.2b	1.4b
General and administrative expense	6.1b	6.9b	8.0b
Operating expense total	6.7b	8.2b	9.6b
EBIT	4.6b	7.8b	10.0b
EBIT margin, %	18%	24%	26%
Interest expense	676.0m	553.0m	536.0m
Interest income	224.0m	65.0m	43.0m
Pre tax profit	4.1b	7.2b	8.8b
Income tax expense	374.0m	850.0m	1.1b
Net Income	3.7b	6.4b	7.7b
EPS	9.2	16.0	19.5

Quarterly

USD	Q1, 2020	Q2, 2020	Q3, 2020	Q1, 2021	Q2, 2021	Q3, 2021	Q1, 2022
Revenue	6.2b	6.9b	8.5b	9.9b	9.3b	9.3b	11.8b
Cost of goods sold	3.5b	3.5b	4.2b	4.7b	4.7b	4.7b	6.4b
Gross profit	2.7b	3.4b	4.3b	5.2b	4.5b	4.7b	5.5b
Gross profit Margin, %	44%	51%	51%	53%	49%	50%	46%
R&D expense	245.0m	264.0m	296.0m	320.0m	343.0m	351.0m	364.0m
General and administrative expense	1.6b	1.7b	1.6b	1.8b	1.9b	2.0b	2.3b
Operating expense total	1.8b	2.0b	1.9b	2.2b	2.4b	2.4b	2.6b
EBIT	906.0m	1.4b	2.4b	3.0b	2.2b	2.3b	2.8b
EBIT margin, %	15%	20%	28%	31%	23%	24%	24%
Interest expense	126.0m	137.0m	144.0m	125.0m	122.0m	128.0m	136.0m
Interest income	36.0m	8.0m	9.0m	12.0m	11.0m	9.0m	18.0m
Pre tax profit	828.0m	1.3b	2.3b	2.8b	2.0b	2.2b	2.5b
Income tax expense	40.0m	97.0m	319.0m	416.0m	219.0m	271.0m	301.0m
Net Income	788.0m	1.2b	1.9b	2.3b	1.8b	1.9b	2.2b
EPS	2.0	2.9	4.8	5.9	4.6	4.8	5.6

Annual

USD	FY, 2019	FY, 2020	FY, 2021
Cash	2.4b	10.3b	4.5b
Accounts Receivable	4.3b	5.7b	8.0b
Inventories	3.4b	4.0b	5.1b
Current Assets	11.9b	22.0b	20.1b
PP&E	4.7b	5.9b	8.3b
Goodwill	25.7b	26.0b	41.9b
Total Assets	58.4b	69.1b	95.1b
Accounts Payable	1.9b	2.2b	2.9b
Short-term debt	676.0m	2.6b	2.5b
Current Liabilities	6.2b	10.3b	13.4b
Long-term debt	17.1b	19.1b	32.3b
Total Debt	17.8b	21.7b	34.9b
Total Liabilities	28.7b	34.5b	54.1b
Common Stock	434.0m	437.0m	439.0m
Additional Paid-in Capital	15.1b	15.6b	16.2b
Retained Earnings	22.1b	28.1b	35.4b
Total Equity	29.7b	34.5b	40.9b
Debt to Equity Ratio	0.6 x	0.6 x	0.9 x
Debt to Assets Ratio	0.3 x	0.3 x	0.4 x
Financial Leverage	2 x	2 x	2.3 x

Quarterly

USD	Q1, 2020	Q2, 2020	Q3, 2020	Q1, 2021	Q2, 2021	Q3, 2021	Q1, 2022
Cash	3.0b	5.8b	7.5b	5.6b	7.0b	12.0b	2.8b
Accounts Receivable	4.5b	4.5b	5.2b	5.6b	5.5b	5.6b	7.9b
Inventories	3.5b	3.6b	3.8b	4.3b	4.6b	4.9b	5.5b
Current Assets	12.7b	15.8b	18.2b	17.7b	19.3b	24.7b	18.8b
PP&E	4.7b	4.9b	5.2b	6.1b	6.6b	7.0b	8.4b
Goodwill	25.6b	25.7b	25.8b	26.8b	26.9b	26.9b	41.7b
Total Assets	58.7b	61.6b	64.1b	65.9b	67.7b	73.6b	92.7b
Accounts Payable	1.6b	1.4b	1.7b	2.1b	2.1b	2.3b	2.7b
Short-term debt	738.0m	675.0m	2.0m	4.0m	4.0m	19.0m	1.9b
Current Liabilities	5.5b	6.0b	6.2b	7.0b	6.9b	7.8b	12.1b
Long-term debt	19.2b	20.6b	21.1b	18.6b	18.8b	21.7b	31.4b
Total Debt	20.0b	21.3b	21.1b	18.6b	18.8b	21.7b	33.3b
Total Liabilities	30.1b	31.7b	32.2b	30.9b	30.8b	34.9b	51.7b
Common Stock	435.0m	436.0m	437.0m	438.0m	438.0m	439.0m	440.0m
Additional Paid-in Capital	15.2b	15.3b	15.5b	15.7b	15.8b	16.0b	16.2b
Retained Earnings	22.8b	23.9b	25.7b	30.4b	32.1b	33.9b	37.5b
Total Equity	28.6b	29.9b	31.8b	35.1b	36.9b	38.7b	41.0b
Debt to Equity Ratio	0.7 x	0.7 x	0.7 x	0.5 x	0.5 x	0.6 x	0.8 x
Debt to Assets Ratio	0.3 x	0.3 x	0.3 x	0.3 x	0.3 x	0.3 x	0.4 x
Financial Leverage	2.1 x	2.1 x	2 x	1.9 x	1.8 x	1.9 x	2.3 x

Annual

USD	FY, 2019	FY, 2020	FY, 2021
Net Income	3.7b	6.4b	7.7b
Depreciation and Amortization	2.3b	2.3b	2.6b
Accounts Receivable	(225.0m)	(1.3b)	(204.0m)
Inventories	(458.0m)	(508.0m)	(1.1b)
Accounts Payable	266.0m	59.0m	479.0m
Cash From Operating Activities	5.0b	8.3b	9.3b
Purchases of PP&E	(926.0m)	(1.5b)	(2.5b)
Cash From Investing Activities	(1.5b)	(1.5b)	(21.9b)
Long-term Borrowings	(9.8b)	(1.1b)	(11.7b)
Dividends Paid	(297.0m)	(337.0m)	(395.0m)
Cash From Financing Activities	(3.1b)	959.0m	6.6b
Net Change in Cash	305.0m	7.9b	(5.8b)
Interest Paid	790.0m	471.0m	555.0m
Income Taxes Paid	896.0m	1.3b	2.2b

Quarterly

USD	Q1, 2020	Q2, 2020	Q3, 2020	Q1, 2021	Q2, 2021	Q3, 2021	Q1, 2022
Net Income	788.0m	1.9b	3.9b	2.3b	4.2b	6.1b	2.2b
Depreciation and Amortization	574.0m	1.1b	1.7b	621.0m	1.3b	(614.0m)	859.0m
Accounts Receivable	(218.0m)	(195.0m)	(858.0m)	149.0m	249.0m	111.0m
Inventories	(141.0m)	(309.0m)	(427.0m)	(352.0m)	(621.0m)	916.0m	499.0m
Accounts Payable	(241.0m)	(497.0m)	(220.0m)
Cash From Operating Activities	356.0m	2.2b	5.0b	2.0b	4.2b	6.9b	2.2b
Purchases of PP&E	(253.0m)	(522.0m)	(888.0m)	(628.0m)	(1.2b)	(1.7b)	(640.0m)
Cash From Investing Activities	(260.0m)	(519.0m)	(884.0m)	(2.0b)	(2.6b)	(3.2b)	(670.0m)
Short-term Borrowings							(1.3b)
Long-term Borrowings	(322.0m)	(389.0m)	(1.1b)	(2.8b)	(2.8b)	(2.8b)	(375.0m)
Dividends Paid	(76.0m)	(163.0m)	(250.0m)	(87.0m)	(190.0m)	(292.0m)	(103.0m)
Cash From Financing Activities	619.0m	1.8b	1.0b	(4.8b)	(4.9b)	(1.9b)	(3.1b)
Net Change in Cash	588.0m	3.4b	5.1b	(4.7b)	(3.3b)	1.7b	(1.7b)
Income Taxes Paid	100.0m	320.0m	656.0m	542.0m	1.3b	1.6b	303.0m

USD	FY, 2019
EV/EBIT	31.7 x
EV/CFO	29.3 x
Revenue/Employee	340.6k
Debt/Equity	0.6 x
Debt/Assets	0.3 x
Financial Leverage	2 x
P/E Ratio	35.4

Thermo Fisher Scientific's Customers was reported to be 400 k in FY, 2020. Thermo Fisher Scientific's Backlog was reported to be $7.8b in FY, 2019.

	FY, 2018	Q1, 2019	Q2, 2019	Q3, 2019	FY, 2019	Q1, 2020	Q2, 2020	Q3, 2020	FY, 2020	Q1, 2021	Q2, 2021	Q3, 2021	FY, 2021
Customers	400 k				400 k				400 k
Remaining Performance Obligations	$5.09 b	$5.57 b	$7.07 b	$6.76 b	$7.77 b	$8.36 b	$9.99 b	$11.16 b	$12.81 b	$13.29 b	$13.56 b	$14.49 b	$28.3 b
Backlog	$5.09 b				$7.77 b
Backlog (Life Sciences Solutions)	$647 m				$893 m
Backlog (Analytical Instruments)	$2.24 b				$2.2 b
Backlog (Specialty Diagnostics)	$187 m				$172 m
Backlog (Laboratory Products and Services)	$2.06 b				$4.58 b

Gender

	FY, 2020	FY, 2019
Female, percent	10.1%	40.4%
Male (Leadership, USA), percent	15.8%
Male, percent	14.4%	58.8%
Female (Leadership, USA), percent	9.3%
Female (Executive Management, USA), percent	7.5%
Male (USA), percent	14.7%
Female (USA), percent	10.3%
Male (Executive Management, USA), percent	17.5%
Other	0.6%	0.8%

Source: corporate.thermofisher.com

Ethnicity

	FY, 2020
Other Ethnicity (USA), percent	21.2%
Other Ethnicity (Leadership, USA), percent	24.8%
Ethnic Minorities (Executive Management, USA), percent	7.4%
People of Color (USA), percent	12.1%
People of Color (Leadership, USA), percent	8.5%
Ethnic Non-Minorities (Executive Management, USA), percent	26%

Source: corporate.thermofisher.com

Culture & Values

3.5

Work/Life Balance

3.3

Senior Management

3.1

Salary & Benefits

3.4

Career Opportunities

3.4

Source

View Thermo Fisher Scientific profile

Competitors

Roche

Manufacturing & Industrial - Public

Abbott

Healthcare - Public

Ingersoll Rand

Manufacturing & Industrial - Public

Danaher

Manufacturing & Industrial - Public

Compare competitors

Thermo Fisher Scientific (TMO) stock price, revenue, and financials

$548.27

$214.7 B

$11.8 B

Thermo Fisher Scientific Revenue

Thermo Fisher Scientific Revenue Breakdown

Thermo Fisher Scientific Income Statement

Annual

Revenue

Revenue growth, %

Cost of goods sold

Gross profit

Gross profit Margin, %

R&D expense

General and administrative expense

Operating expense total

EBIT

EBIT margin, %

Interest expense

Interest income

Pre tax profit

Income tax expense

Net Income

EPS

Quarterly

Revenue

Cost of goods sold

Gross profit

Gross profit Margin, %

R&D expense

General and administrative expense

Operating expense total

EBIT

EBIT margin, %

Interest expense

Interest income

Pre tax profit

Income tax expense

Net Income

EPS

Thermo Fisher Scientific Balance Sheet

Annual

Cash

Accounts Receivable

Inventories

Current Assets

PP&E

Goodwill

Total Assets

Accounts Payable

Short-term debt

Current Liabilities

Long-term debt

Total Debt

Total Liabilities

Common Stock

Additional Paid-in Capital

Retained Earnings

Total Equity

Debt to Equity Ratio

Debt to Assets Ratio

Financial Leverage

Quarterly

Cash

Accounts Receivable

Inventories

Current Assets

PP&E

Goodwill

Total Assets

Accounts Payable

Short-term debt

Current Liabilities

Long-term debt

Total Debt

Total Liabilities

Common Stock

Additional Paid-in Capital

Retained Earnings

Total Equity